Serina Therapeutics, Inc. Proceeds from Lines of Credit
Serina Therapeutics, Inc. (SER) reported Proceeds from Lines of Credit of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-03-25
- Serina Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. proceeds from lines of credit for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Serina Therapeutics, Inc. proceeds from lines of credit for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Serina Therapeutics, Inc. proceeds from lines of credit for fiscal 2024 was $3.04M.
- Serina Therapeutics, Inc. proceeds from lines of credit for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Serina Therapeutics, Inc. proceeds from lines of credit for fiscal 2022 was $6.00M, a 14.29% decline from fiscal 2021.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 9 month as first filed | Proceeds from Lines of Credit 12 month | Proceeds from Lines of Credit 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $0.00 derived: sum of 2 quarters · filed 2026-03-25 | $0.00 derived: sum of 3 quarters · filed 2026-03-25 | $0.00 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $110.00K derived: sum of 4 quarters · filed 2026-03-25 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $110.00K derived: sum of 3 quarters · filed 2026-03-25 | $118.00K derived: sum of 4 quarters · filed 2026-03-25 | ||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $110.00K derived: sum of 2 quarters · filed 2026-03-25 | $118.00K derived: sum of 3 quarters · filed 2026-03-25 | $643.00K derived: sum of 4 quarters · filed 2026-03-25 | ||
| 2024-12-31 | $110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $118.00K derived: sum of 2 quarters · filed 2026-03-25 | $643.00K derived: sum of 3 quarters · filed 2026-03-25 | $3.04M 10-K · filed 2026-03-25 | ||
| 2024-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $533.00K derived: sum of 2 quarters · filed 2025-11-13 | $2.93M 10-Q · filed 2025-11-13 | $2.93M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $525.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $2.92M 10-Q · filed 2025-08-11 | $2.92M derived: sum of 3 quarters · filed 2025-08-11 | -$10.57M derived: sum of 4 quarters · filed 2025-08-11 | ||
| 2024-03-31 | $2.40M 10-Q · filed 2025-05-08 | $2.40M derived: sum of 2 quarters · filed 2025-05-08 | -$11.10M derived: sum of 3 quarters · filed 2025-05-08 | -$9.10M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$13.50M derived: sum of 2 quarters · filed 2025-03-24 | -$11.50M derived: sum of 3 quarters · filed 2025-03-24 | $0.00 10-K · filed 2025-03-24 | $17.50M 10-K · filed 2024-03-22 | |
| 2023-09-30 | -$13.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$11.50M derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | $15.50M 10-Q · filed 2023-11-14 | $1.50M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $13.50M 10-Q · filed 2023-08-14 | $15.00M derived: sum of 3 quarters · filed 2024-03-22 | $16.00M derived: sum of 4 quarters · filed 2024-03-22 | ||
| 2023-03-31 | $11.50M 10-Q · filed 2023-05-12 | $13.00M derived: sum of 2 quarters · filed 2024-03-22 | $14.00M derived: sum of 3 quarters · filed 2024-03-22 | $16.00M derived: sum of 4 quarters · filed 2024-03-22 | ||
| 2022-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $2.50M derived: sum of 2 quarters · filed 2024-03-22 | $4.50M derived: sum of 3 quarters · filed 2024-03-22 | $6.00M 10-K · filed 2024-03-22 | ||
| 2022-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.00M derived: sum of 2 quarters · filed 2023-11-14 | $4.50M 10-Q · filed 2023-11-14 | $6.00M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.50M 10-Q · filed 2023-08-14 | $5.00M derived: sum of 3 quarters · filed 2023-08-14 | $7.00M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $1.50M 10-Q · filed 2023-05-12 | $3.00M derived: sum of 2 quarters · filed 2023-05-12 | $5.00M derived: sum of 3 quarters · filed 2023-05-12 | $6.50M derived: sum of 4 quarters · filed 2023-05-12 | ||
| 2021-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $3.50M derived: sum of 2 quarters · filed 2023-03-31 | $5.00M derived: sum of 3 quarters · filed 2023-03-31 | $7.00M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.50M derived: sum of 2 quarters · filed 2022-11-10 | $5.50M 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | $1.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $3.50M 10-Q · filed 2022-08-12 | ||||
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-13 | |||||
| 2020-12-31 | $5.70M 10-K · filed 2021-03-31 | |||||
| 2019-12-31 | $1.80M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |